neurotrophic keratopathy

Neurotrophic keratopathy is a rare degenerative disease of the cornea characterized by a reduction or loss of corneal sensitivity. This condition can be asymptomatic or present with symptoms such as red-eye and a minor decrease in visual acuity during early stages. Over time, it leads to significant vision loss. Currently, no specific genes have been identified, and the inheritance pattern remains unestablished. The prevalence of this condition is unknown, which contributes to the limited clinical documentation.

The documentation for neurotrophic keratopathy is limited primarily due to its rarity, which affects fewer than 200,000 people in the U.S. This rarity results in fewer systematic clinical studies and a lack of comprehensive data on the condition. Additionally, the absence of identified genes and established inheritance patterns complicates the understanding of its clinical features.

There are currently 15 active clinical trials investigating various treatments for neurotrophic keratopathy. , the FDA has approved cenegermin-bkbj as a treatment option. Other drugs in development include allogeneic human blood serum, exosomes purified from primed human bone marrow derived mesenchymal stem cells, and several peptides. For more information on ongoing trials, you can visit ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=neurotrophic%20keratopathy.